Health Care • Biotechnology: Pharmaceutical Preparations
$273.99 ▼ -11.94
(-4.18%)
MKT CAP: $7.98B • VOL: 312.4K
52W L $154 52W H $393
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$230
MEDIAN
$307
MEAN
$312
HIGH
$373
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE PRAX TAPE
PRAX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $331.53 | $315.09 | 2025-02-14 | $249.33 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $345.23 | $323.31 | 2025-02-06 | $257.55 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $312.35 | $301.39 | 2025-01-29 | $263.03 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $279.47 | — | 2025-01-17 | $268.51 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $241.11 | $260.29 | 2025-01-09 | $243.85 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $326.05 | $284.95 | 2024-12-18 | $238.37 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $265.77 | $276.73 | 2024-12-04 | $254.81 | -4.3% | 48% | C |